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INTRODUCTION  26	
Real time glycemia is a cornerstone for metabolic research, particularly when 27	
performing oral glucose tolerance tests (OGTT) or glucose clamps. From 1965 to 2009, the 28	
gold standard device for real time plasma glucose assessment was the Beckman glucose 29	
analyzer 2 (Beckman Instruments, Fullerton, CA), which technology couples glucose oxidase 30	
enzymatic assay with oxygen sensors. Since its discontinuation in 2009, today’s researchers 31	
are left with few choices that utilize glucose oxidase technology. The first one is the YSI 2300 32	
(Yellow Springs Instruments Corp., Yellow Springs, OH), known to be as accurate as the 33	
Beckman(1). The YSI has been used extensively for clinical research studies and is used to 34	
validate other glucose monitoring devices(2). The major drawback of the YSI is that it is 35	
relatively slow and requires high maintenance. The Analox GM9 (Analox instruments, 36	
London), more recent and faster, is increasingly used in clinical research(3) as well as in basic 37	
sciences(4) (e.g. 23 papers in Diabetes or 21 in Diabetologia).  38	
Although a report from the Analox manufacturer shows good linearity in a wide range 39	
of glucose concentrations; data assessing its reliability and agreement in clamp and OGTT 40	
conditions are scarce. The aim of this study was to assess whether or not the Analox is 41	
accurate to serve as a replacement for the YSI during clamp and OGTT studies. Our goal was 42	
to analyze the association, reliability and agreement between the two devices, in order to 43	
confirm their interchangeability for clinical research.  44	
 45	
METHODS 46	
Two hundred ninety three plasma specimens from 13 OGTT and hyperinsulinemic 47	
euglycemic clamps from subjects recruited in our ongoing research study were used for this 48	
comparison. All subjects signed the IRB approved consent.  49	
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Immediately after drawing, 0.4 ml of blood was placed in microtubes containing 30 50	
I.U. of Lithium-Heparin and 1 mg Sodium Fluoride per ml of blood as glucose preservative. 51	
Both of these chemicals are known not to interfere with glucose oxidase measurements. 52	
Microtubes were spun in a microcentrifuge and plasma was loaded simultaneously on both 53	
the YSI and the Analox. These were previously calibrated as specified by the manufacturers. 54	
Calibrations were repeated throughout the OGTT or clamps. Manufacturer’s standards of 55	
various known concentrations were used to assess quality of calibration throughout the tests. 56	
All solutions were kept at 4 degrees Celsius as suggested by the manufacturers. 57	
To analyze absolute differences, paired-sample T-tests were performed between YSI 58	
and Analox results. Simple linear regression was used to confirm linear relationship and its 59	
dispersion was assessed by standard error of estimation (SEE). To assess repeatability, the 60	
regression line was compared to the identity line. Concordance correlation coefficient (CCC), 61	
which contains both measurements of precision (p, Pearson correlation coefficient) and 62	
accuracy (Cb, bias correction factor), was also computed. To confirm agreement a 63	
Bland&Altman Plot was done. Reliability was assessed using intraclass coefficient correlation 64	
(ICC), technical error of measurement (TEM) and coefficient of reliability (R). The 65	
percentage of TEM (%TEM) was considered as a measure of inter-device coefficient of 66	
variation. All analyses were performed using PASW for Windows version 20.0 (SPSS Inc., an 67	
IBM Company, Chicago, IL) and MedCalc Statistical Software (MedCalc Software, 12.4.0.0, 68	
Belgium). For all tests, statistical significance was set at P<0.05. 69	
 70	
RESULTS 71	
A mean significant difference of 1.05 mmol/L was found between Analox and YSI 72	
(P<0.001), indicating a systematic error. Pearson’s correlation (r=0.777;P<0.001) and linear 73	
regression (R2=0.604;P<0.001) are presented in figure 1A. The SEE was 0.83 mmol/L. A 74	
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broad dispersion was observed in the euglycemic range (r=0.341, R2=0.116, both P<0.001) 75	
with SEE= 0.86 mmol/L. In values higher than 6.1 mmol/L, dispersion was lesser (r= 0.994, 76	
R2=0.987, both P<0.001) with SEE=0.19 mmol/L.  77	
Repeatability results indicated weak precision (p=0.777) and accuracy (Cb= 0.712), 78	
with a low CCC (0.554). The Bland&Altman plot (Figure 1B) illustrated that the higher the 79	
glycemia, the higher the difference. There was a significant proportional bias (Kendall’s 80	
Tau=-0.403, P<0.001).  81	
Reliability was weak with an ICC of 0.865 (P<0.001) and high TEM and %TEM 82	
(1.89 mmol/L and 31.9%, respectively). The coefficient of reliability was very low (R=0.234). 83	
 84	
DISCUSSION 85	
The main finding of this study was that glycemia measured from YSI and Analox 86	
were significantly different with both systematic and proportional errors. To our knowledge 87	
this is the only study comparing the Analox to the YSI that can be seen as today’s gold 88	
standard(5). We did not find an acceptable agreement between the YSI and the Analox. 89	
Reliability and concordance were modest. In addition, the Analox overestimated 99.7% of the 90	
specimens. 91	
Our results are in disagreement with the manufacturer information comparing 123 92	
specimens measured by Analox and Beckman (http://www.analoxusa.com/analoxgm9info.htm). 93	
They reported a well-fitted linear equation Y=1.005·X-0.073 (R2=0.998) which contrasts with the 94	
one reported in this study Y=0.947·X+1.334 (R2=0.604). This discrepancy may be partially 95	
explained by the wide range of concentrations used by the manufacturer to validate the GM9 96	
(from 3.00 to 23.98 mmol/L) and the fact that few samples were in the euglycemic range, which 97	
may introduce bias(6) and increase type I error. In contrast, we used human specimens in 98	
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physiological range covering euglycemia and hyperglycemia, and increased the sample size by a 99	
factor of 2.4.  100	
Although this may not be a problem for clinical diagnostic (it can be assumed that 101	
clinical diagnosis is done based on clinical chemistry laboratories using automated machines), 102	
it could have major implications for clinical studies. In our ongoing studies, we screen 103	
volunteers to exclude diabetic (DM) and include in different groups those that are impaired 104	
glucose tolerant (IGT) or normal glucose tolerant (NGT). Based on 2 hours OGTT glycemia 105	
and ADA criteria, among 54 subjects screened, 33 were NGT (61%), 18 IGT (33%) and 3 106	
DM (6%) with the YSI, and 18 NGT (33%), 29 IGT (54%) and 7 DM (13%) with the Analox. 107	
Thus, if using the Analox, we would have excluded more subjects and unfittingly created 108	
study groups.  109	
The main limitations of this study is that we did not compare the YSI and the Analox 110	
against the Beckman. A recent study(7) compared another available glucose oxidase device 111	
against both the Beckman and the YSI. They determined a complete agreement between the 112	
YSI and the Beckman in the range observed by our study (below 13 mmol/L). Although we 113	
did not directly assess manufacturer’s reagents variability, calibrations were controlled by the 114	
use of manufacturer’s standards of different concentrations. Sensors were controlled by the 115	
manufacturers and did not present signs of damage that could explain the differences 116	
observed. 117	
In conclusion, we propose to use caution when using the Analox GM9 for clinical 118	
research. The measurement bias observed in this study could have consequences 119	
encompassing misinformed categorization in different study groups based on glucose 120	
tolerance tests, misinterpretation of glucose kinetics and inability to compare among studies.  121	
 122	
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FIGURE	LEGEND	167	
	168	
Figure 1. 169	
Panel A Scatter plot of glycemias from Analox and YSI analyzers. White circles=YSI 170	
glycemia ≤6.1 mmol/L. Black circles=glycemia >6.1 mmol/L. Dashed line=linear regression 171	
line. Solid line=identity line.   172	
Panel B Bland & Altman plot for agreement analyses between YSI and Analox glucose 173	
measurements. Solid line=zero. Dashed line=mean differences between methods (systematic 174	
error). Dotted line=trend between differences and means (proportional bias).  Dotted-dash 175	
lines=intervals of concordance.  176	
 177	
Figure	1	
	
A	
	
	
	
B	
	
	
	
